Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 single- and multiple-ascending-dose study of KY1005 in healthy volunteers
NL-OMON45487Phase 1Active, not recruiting
- Sponsor
- Kymab
- Start
- May 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, double-blind trial of amlitelimab (2 arms), sponsored by Kymab. Primary endpoint: Safety and tolerability of KY1005. Started May 2017; status: active, not recruiting.
02
Drugs
amlitelimab
Beyond the preview
Go deeper on NL-OMON45487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45487.